The cost of most drugs used in multiple myeloma is approximately 100,000 dollars per year and combination regimens with a Proteosome inhibitor, immunomodulatory agent, and an anti CD-38 targeted monoclonal antibody costs 300,000—600,000 US dollars per year [9]. This evidence concerns the gene CD38 and plasma cell myeloma.